1.

What are the key strengths and weaknesses of real-world data compared to data from randomized controlled trials?
Cardiologist's Perspective - 2:54
 

2.

How would you summarize the key real-world data for DOACs in patients with AF?
Cardiologist's Perspective - 1:51
 

3.

Overall, what are the key insights from real-world data with DOACs which you find most relevant to clinical practice in treating patients with AF?
Cardiologist’s Perspective — 3:07
Neurologist’s Perspective — 0:15
ER Physician’s Perspective — 1:21
 

4.

How would you rank the most important characteristics of an anticoagulant for stroke prevention in AF? What would be your “top 3” and is there a hierarchy of importance?
Cardiologist’s Perspective — 2:03
Neurologist’s Perspective — 0:23
ER Physician’s Perspective — 2:44
 

5.

When should we interrupt or restart a DOAC for a procedure in patients with AF?
Cardiologist's Perspective - 2:33
Neurologist's Perspective - 1:20

6.

In terms of efficacy, which DOAC(s) would you recommend for use in a patient with AF with a high risk of stroke?
Cardiologist’s Perspective — 2:17
Neurologist’s Perspective — 0:41
 

7.

How should anticoagulation be managed in a patient with AF who has experienced GI bleeding or is at high risk of bleeding?
Cardiologist's Perspective - 3:32
ER Physician's Perspective - 2:45
 

8.

How does the presence of renal impairment impact your choice of DOAC for stroke prevention in patients with AF?
Cardiologist’s Perspective — 3:36
Neurologist’s Perspective — 1:27
ER Physician’s Perspective — 2:34
 

9.

What additional aspects of care should be kept in mind when prescribing anticoagulant therapy for stroke prevention among frail elderly patients with AF?
Cardiologist’s Perspective — 4:18
Neurologist’s Perspective — 1:29
ER Physician’s Perspective — 4:04
 

10.

When and how should anticoagulant reversal be handled in patients with AF?
ER Physician's Perspective - 4:37